Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has licensed a portfolio of preclinical triple reuptake inhibitor compounds for depression from Mayo Clinic and Virginia Tech Intellectual Properties. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
Subscribe to our email newsletter
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel triple reuptake inhibitor (TRI) compounds. Financial details were not disclosed.
Christer Kohler, vice president for AstraZeneca’s global discovery research area focused on central nervous system & pain, said: “Besides enabling us to harness the combined power of two institutions, this agreement also establishes a strong footing for AstraZeneca in the strategically important TRI research area.
“We continue to build alliances and collaborations within the scientific community and this deal is another example of our strong commitment and ability to leverage innovation with the aim of making a meaningful difference in patients’ lives.”